Drug Profile
Tavapadon - Cerevel Therapeutics
Alternative Names: CVL 751; PF 6649751; PF-06649751Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Parkinson's disease
Most Recent Events
- 18 Apr 2024 Efficacy and adverse events data from the phase III trial in Parkinson's disease released by Cerevel Therapeutics
- 17 Dec 2023 Cerevel Therapeutics completes a phase I trial for Parkinson's disease (Adjunctive treatment) in USA (PO, Tablet) (NCT05610189)
- 14 Aug 2023 Cerevel Therapeutics completes a phase I trial in Renal impairment in USA (PO) (NCT05404542)